Skip to main content
OpenTrials
Completed

NCT Number: NCT06659666

The COPD Optimiser

Rationale: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) report pro- vides clinical treatment guidelines for COPD aimed at relieving and reducing the impact of symptoms, and reducing the risk of adverse health events, such as exacerbations. Despite the availability of these COPD treatment guidelines, evidence suggests that available thera- pies may not be utilized to their full potential to optimize disease management and outcomes for patients. So far, there is a lack of knowledge on the optimalisation opportunities of patients with COPD in a primary care setting.

Objective: The primary objective is to describe the GOLD-guided management suggestions obtained from the COPD Optimiser, in order to gain insight into optimalisation opportunities in a Dutch primary care population of patients with COPD.

Study design: This is a non-interventional prospective observational study, taking place in a real-world primary care setting.

Study population: Patients diagnosed with COPD are eligible to participate. A limited number of in- and exclusion criteria will be adopted, to make sure the research population closely resembles the real world.

ature and extent of the burden and risks associated with participation, benefit and group relatedness: Study specific involvement is limited to the one visit for the participant. Participants will receive enhanced usual medical care as determined by their physician and will not be randomly allocated to an experimental intervention or care as usual. The partici- pating general practices and participants in the study will be reimbursed for the time spent on this study. Risks of participating in the study are deemed to be negligible. All participants will use their own medication and follow the management plan that is in line with guidelines. The study specific additions to the consultation are administering a (not emotionally demanding) questionnaire and drawing a small amount of blood from the finger, to measure the level of blood eosinophils, using a point-of-care method. This is a test that may cause a slight incon- venience for the patient, although this test is less invasive than typical blood draws that would be part of the newest international guideline.

Primary objective

1. Describe the GOLD-guided management suggestions obtained from the COPD Optimiser, in order to gain insight into optimalisation opportunities in a Dutch primary care pop- ulation of patients with COPD. The endpoint for the primary objective is the number of times that each manage- ment suggestion was given

Completed

Looking for future studies?

Notify Me

Key information

Age range

35 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

GPRI, Groningen, Provincie Groningen, Netherlands

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Physician diagnosis of COPD (ICPC R95),
  • Capacity to understand and provide written informed consent.

Exclusion criteria

  • Active diagnosis of Asthma (ICPC R96)
  • Patients participating in an interventional clinical trial

Treatment and study plan

COPD Optimiser

Device

Patients will receive enhanced usual medical care as determined by their physician. The study visit is a standard consultation supported by the COPD Optimiser webtool. The extra elements added to the COPD consultation are the use of the COPD Optimiser and a short questionnaire directly following the consultation on the patient's experience with the COPD Optimiser. Patients can additionally consent to two optional elements: 1) a determination of blood eosinophil count using a point of care test and 2) a brief interview on their experience with the COPD Optimiser. this tool creates an overview of fac- tors and characteristics that may be associated with suboptimal COPD and provides GOLD guideline-based management suggestions. Implementation of the COPD Optimiser will sup- port healthcare professionals in providing optimal care for their COPD patients by providing individualized GOLD-guided management suggestions.

Primary outcomes

  1. patterns of co-occurrence of GOLD-guided management suggestions in a Dutch primary care population of patients with COPD.

    Time frame: Immediately after the procedure

    The primary endpoint is the number of times that each management suggestion was given. With this endpoint, we can describe the proportion of primary care patients with COPD of whom disease management can be optimized per GOLD-guided management suggestions from the COPD Optimiser. Incidence will be described for each of the possible management suggestions from the COPD Optimiser.

Secondary outcomes

  1. Co-occurance and concordance of GOLD-based management suggestions

    Time frame: Immediately after the procedure

    The secondary study endpoints are

    • The presence of co-occurring GOLD-guided management suggestions from the COPD Optimiser in primary care patients with COPD
    • The proportion of patients for whom the current medication regimen is not in line with the GOLD pharmacological treatment recommendation, either:
    • The proportion of patients that received a GOLD-guided step-up advice from the COPD Optimiser
    • The proportion of patients that received a GOLD-guided step-down advice from the COPD optimiser

Other outcomes

  1. User experience of healthcare providers & participants

    Time frame: Immediately after the procedure for SUS. For the exploratory interviews, through study completion, within 12 weeks of study end

    The endpoint for the user experience of the healthcare provider is captured by employing the System Usability Scale, adapted to Dutch (SUS-D). This questionnaire explores the perceived usefulness and ease of use of the tool. We will add questions about the likelihood to act upon the management suggestions from the COPD optimiser, as well as the likelihood to continue the use of the COPD optimiser in the future.

    For participants, the exploratory parameters are their experience during the visit (in comparison with previous COPD consultations) (e.g. duration, relevance of questions, actions after the consultation).

Sponsors and collaborators

Lead sponsor

General Practitioners Research Institute

Network

Collaborators

  • AstraZeneca

Registry information

Official study title

Opportunities to Optimize COPD Management Using the COPD Optimiser Online Tool in Dutch General Practice

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Oct 26, 2024
Registry last updated
Dec 26, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.